Cancer biotherapy最新文献_第7页

In vitro effects of pentoxifylline and doxorubicin on cell survival and DNA damage in sensitive and MDR-P388 leukemia cells. 己酮茶碱和阿霉素对敏感和耐多药p388白血病细胞存活和DNA损伤的体外影响

Cancer biotherapy Pub Date : 1994-01-01 DOI: 10.1089/cbr.1994.9.143

A Viladkar, M Chitnis

{"title":"In vitro effects of pentoxifylline and doxorubicin on cell survival and DNA damage in sensitive and MDR-P388 leukemia cells.","authors":"A Viladkar, M Chitnis","doi":"10.1089/cbr.1994.9.143","DOIUrl":"https://doi.org/10.1089/cbr.1994.9.143","url":null,"abstract":"The utility of chemosensitizers to improve efficacy of chemotherapy is now gaining importance. This report investigated whether an active hemorheological agent, pentoxifylline (PTX), can circumvent drug resistance in parental (P388/S) and multidrug resistant (P388/DOX) P388 leukemia cells. For detection of doxorubicin (DOX) resistance and reversal of this resistance by PTX, the incorporation of nucleic acid precursor was measured after addition of DOX and PTX, respectively. The effect of PTX on the induction of DNA strand breaks by DOX was also examined. Increased fragmentation of DNA was illustrated in P388/DOX leukemia cells exposed to the combination of DOX and PTX. The most prominent feature of the multidrug-resistant cell is the reduced accumulation of the drug intracellularly. P388/DOX cells showed less accumulation of DOX in the cell as compared to that of the parental cell line. Further studies demonstrated that PTX significantly enhanced the intracellular accumulation of DOX in both the cell lines. These studies warrant the use of PTX as an adjuvant in cancer chemotherapy.","PeriodicalId":79322,"journal":{"name":"Cancer biotherapy","volume":"9 2","pages":"143-51"},"PeriodicalIF":0.0,"publicationDate":"1994-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cbr.1994.9.143","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18812768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 10

Cancer research: does it deliver for the patient? 癌症研究:对病人有效吗?

Cancer biotherapy Pub Date : 1994-01-01 DOI: 10.1089/cbr.1994.9.99

R K Oldham

引用次数: 3

Suppressive effects on cancer cell proliferation of the enhancement of superoxide dismutase (SOD) activity associated with the protein-bound polysaccharide of Coriolus versicolor QUEL. 提高花椒蛋白结合多糖超氧化物歧化酶(SOD)活性对癌细胞增殖的抑制作用。

Cancer biotherapy Pub Date : 1994-01-01 DOI: 10.1089/cbr.1994.9.171

Y Kobayashi, K Kariya, K Saigenji, K Nakamura

{"title":"Suppressive effects on cancer cell proliferation of the enhancement of superoxide dismutase (SOD) activity associated with the protein-bound polysaccharide of Coriolus versicolor QUEL.","authors":"Y Kobayashi, K Kariya, K Saigenji, K Nakamura","doi":"10.1089/cbr.1994.9.171","DOIUrl":"https://doi.org/10.1089/cbr.1994.9.171","url":null,"abstract":"The protein-bound polysaccharide of Coriolus versicolor QUEL (PS-K) expresses superoxide dismutase (SOD) mimicking activity. Examination was made of the suppressive effects of PS-K on cancer cell lines cultured in vitro. SOD activity of incorporated PS-K was 5.88 u/mg in LLC-WRC-256 (Walker 256 fibrosarcoma) cells and 4.73 u/mg in NRK-49F (rat normal kidney fibroblast) cells. SOD activity in both cell types was enhanced about 7-8 times that of the original PS-K. PS-K was not incorporated into H4-11-E or H4-11-E-C3 (rat hepatoma) cells. SOD activity of 1 mg/ml PS-K incubated with cell homogenates of LLC-WRC-256 cells for 6 hours increased from 0.68 u/mg to 1.35 u/mg. SOD activity of PS-K 1 mg/ml in 0.05 M phosphate buffer incubated with 50 microM NADPH increased from 0.68 u/mg. The consumption of NADPH at the same concentration was confirmed spectrophotometically by incubation with PS-K. The mechanism for the enhancement of SOD activity associated with PS-K is considered to be collaboration with NADPH as an electron donor in the cytoplasm of cancer cells whose SOD and coupling enzyme activities are significantly lower than in normal cells.","PeriodicalId":79322,"journal":{"name":"Cancer biotherapy","volume":"9 2","pages":"171-8"},"PeriodicalIF":0.0,"publicationDate":"1994-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cbr.1994.9.171","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18812770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 15

Cancer biotherapy: the first year. 癌症生物疗法:第一年。

Cancer biotherapy Pub Date : 1994-01-01 DOI: 10.1089/cbr.1994.9.179

R K Oldham

引用次数: 8

Immunotherapy with low-dose interleukin-2 and anti-transforming growth factor-beta antibody in a murine tumor model. 低剂量白细胞介素-2和抗转化生长因子- β抗体对小鼠肿瘤模型的免疫治疗。

Cancer biotherapy Pub Date : 1994-01-01 DOI: 10.1089/cbr.1994.9.317

X W Mao, J D Kettering, D S Gridley

{"title":"Immunotherapy with low-dose interleukin-2 and anti-transforming growth factor-beta antibody in a murine tumor model.","authors":"X W Mao, J D Kettering, D S Gridley","doi":"10.1089/cbr.1994.9.317","DOIUrl":"https://doi.org/10.1089/cbr.1994.9.317","url":null,"abstract":"The purpose of the present study was to evaluate the therapeutic efficacy of low-dose interleukin-2 (IL-2) alone or together with antibody against transforming growth factor-beta (TGF-beta) in a Herpes simplex virus Type 2-transformed (H238) fibrosarcoma model. BALB/c mice were inoculated subcutaneously (s.c.) with 5 x 10(5) H238 tumor cells in one or both hind thighs and treated with IL-2, anti-TGF-beta, or a combination of both agents. Nontreated tumor-bearing and normal animals served as controls. In the appropriate treatment groups, each mouse was given a total of 10(5) international units (i.u.) of IL-2 s.c. at one tumor implantation site and/or 1 microgram of anti-TGF-beta intraperitoneally (i.p.) over a period of 5 days beginning on the day of tumor cell implantation. No toxicity was noted during treatment. The slowest tumor growth was observed in mice with single tumors when treated with IL-2 or anti-TGF-beta alone, whereas combination treatment resulted in growth similar to that of untreated controls. However, in animals with two tumors, the tumor injected with IL-2 grew more rapidly than the untreated one. Spleen cell responsiveness to mitogenic stimulation was generally depressed in tumor-bearing mice compared to normal controls, but some differences were noted with treatment. In contrast, tumor presence induced striking splenomegaly and enhanced the chemiluminescent oxidative burst of phagocytic cells in the spleen. In the groups with a single tumor, plasma TGF-beta levels were similar to those of nontumor-bearing controls, however the concentrations were decreased in the animals with two tumors. These results show that IL-2 or anti-TGF-beta can slow progression of H238 tumors under certain conditions. However, combination of the two modalities proved to be of no benefit.","PeriodicalId":79322,"journal":{"name":"Cancer biotherapy","volume":"9 4","pages":"317-27"},"PeriodicalIF":0.0,"publicationDate":"1994-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cbr.1994.9.317","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18723685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 10

Cytokines and the rational choice of immunological adjuvants. 细胞因子与免疫佐剂的合理选择。

Cancer biotherapy Pub Date : 1994-01-01 DOI: 10.1089/cbr.1994.9.1

A W Heath

引用次数: 1

Oxidative stress relief for cancer-bearing hosts by the protein-bound polysaccharide of Coriolus versicolor QUEL with SOD mimicking activity. 具有SOD模拟活性的花椒蛋白结合多糖对癌症宿主氧化应激的缓解作用。

Cancer biotherapy Pub Date : 1994-01-01 DOI: 10.1089/cbr.1994.9.55

Y Kobayashi, K Kariya, K Saigenji, K Nakamura

引用次数: 17

Gene therapy for B-cell lymphoma in a SCID mouse model using an immunoglobulin-regulated diphtheria toxin gene delivered by a novel adenovirus-polylysine conjugate. 利用一种新型腺病毒-聚赖氨酸偶联物递送的免疫球蛋白调节白喉毒素基因治疗SCID小鼠模型中的b细胞淋巴瘤。

Cancer biotherapy Pub Date : 1994-01-01 DOI: 10.1089/cbr.1994.9.131

D R Cook, I H Maxwell, L M Glode, F Maxwell, J O Stevens, M B Purner, E Wagner, D T Curiel, T J Curiel

{"title":"Gene therapy for B-cell lymphoma in a SCID mouse model using an immunoglobulin-regulated diphtheria toxin gene delivered by a novel adenovirus-polylysine conjugate.","authors":"D R Cook, I H Maxwell, L M Glode, F Maxwell, J O Stevens, M B Purner, E Wagner, D T Curiel, T J Curiel","doi":"10.1089/cbr.1994.9.131","DOIUrl":"https://doi.org/10.1089/cbr.1994.9.131","url":null,"abstract":"Despite advances in conventional therapy, many lives continue to be lost to common forms of B-cell cancers, including leukemias, lymphomas and multiple myeloma. We propose a novel approach to therapy of such cancers using controlled expression of a diphtheria toxin gene (DT-A) to kill malignant cells. We have previously demonstrated selective killing of various cell types, in vitro and in vivo, by cell-specific, transcriptionally controlled expression of this gene. Organ-specific ablation in otherwise healthy transgenic mice has convincingly demonstrated the exquisite specificity achievable by this technique. In the studies now described, DT-A was delivered in vitro and in vivo using a novel gene delivery system employing DNA physically attached to the exterior of adenovirus. After demonstrating the efficacy of gene delivery to Epstein-Barr virus transformed human B-cells in vitro, in vivo work was performed using a SCID mouse model for B-cell lymphoma, in which protection against tumor was observed. The concepts of tissue-regulated toxin gene therapy, and this novel adenovirus gene delivery system are discussed.","PeriodicalId":79322,"journal":{"name":"Cancer biotherapy","volume":"9 2","pages":"131-41"},"PeriodicalIF":0.0,"publicationDate":"1994-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cbr.1994.9.131","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18812767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The clinical experience with interleukin-2 in cancer therapy. 白细胞介素-2在肿瘤治疗中的临床体会。

Cancer biotherapy Pub Date : 1994-01-01 DOI: 10.1089/cbr.1994.9.183

R O Dillman

{"title":"The clinical experience with interleukin-2 in cancer therapy.","authors":"R O Dillman","doi":"10.1089/cbr.1994.9.183","DOIUrl":"https://doi.org/10.1089/cbr.1994.9.183","url":null,"abstract":"In May 1992, interleukin-2 (IL-2) was formally approved by the U.S. Food and Drug Administration for use in cancer treatment based on its activity in metastatic renal cell carcinoma. IL-2 alone or in combination with activated lymphocytes or other cytokines has significant anti-tumor activity against renal cell carcinoma and melanoma with response rates of 15-20%, some of which are quite durable. Limited anti-tumor effects have been noted in some patients with colorectal cancer and lymphoma. Too few patients have been studied to establish the level of activity in most other specific tumor types. The mechanism of this anti-tumor effect appears to be entirely mediated by the immunostimulatory effects of IL-2. Toxicities are dose related, but are substantial and similar regardless of the schedule of administration. Randomized trials have failed to establish (1) the superiority of high-dose bolus over continuous infusion IL-2, (2) the superiority of IL-2 plus interferon over IL-2 alone, or (3) the superiority of IL-2 plus LAK cells versus IL-2 alone. Further investigation is needed to determine the optimum dose and schedule from the standpoint of cost:benefit and risk:benefit, and to determine the role of IL-2 in the therapy of other malignant diseases.","PeriodicalId":79322,"journal":{"name":"Cancer biotherapy","volume":"9 3","pages":"183-209"},"PeriodicalIF":0.0,"publicationDate":"1994-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cbr.1994.9.183","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18820603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 40

Leukemia after chemotherapy for cancer. 癌症化疗后的白血病。

Cancer biotherapy Pub Date : 1993-01-01 DOI: 10.1089/cbr.1993.8.115

M R Chasen, G Falkson

引用次数: 0